Abstract Cancer care delivery in low- and middle-income settings faces persistent challenges related to increasing disease burden, delayed presentation, and limited healthcare infrastructure. Bihar, India, a predominantly rural and socioeconomically underserved state, lacked dedicated comprehensive tertiary oncology se...
Ravikant Singh, Naresh Gupta, Nishant Kumar et al.· Indian Journal of Medical an...· 0 citations
By identifying low-risk patients within the NCCN high-risk group and high-risk patients within the NCCN low + intermediate-risk group for recurrence, these models may support treatment de-escalation and escalation, respectively, pending prospective multicenter validation.
N. Chakrabarty, S. Rane, U. Sherkhane et al.· Frontiers in Oncology· 1 citation
KRAS-mutant NSCLC is transitioning from historically untargetable disease to a therapeutically actionable subset, and future progress hinges on resistance-directed combinations, biomarker-guided personalization, expansion to non-G12C mutants, and evaluation in earlier disease settings.
A. Kapoor, Bipinesh Sansar, Anuj Gupta et al.· Medical Oncology· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.